D.E. Shaw & Co
BLCM

D.E. Shaw & Co’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

D.E. Shaw & Co’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,681
Closed -$151K – 4366
2019
Q4 		$151K Buy
11,681
+10,594
+975% +$97.8K ﹤0.01% 3840
2019
Q3 		$11K Buy
+1,087
New +$14.2K ﹤0.01% 3764
2017
Q4 		– Sell
-2,929
Closed -$338K – 3794
2017
Q3 		$338K Buy
2,929
+59
+2% +$6.21K ﹤0.01% 3096
2017
Q2 		$335K Buy
+2,870
New +$356K ﹤0.01% 2991

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

D.E. Shaw & Co's BLCM Position: Q1 2020 in Review

D.E. Shaw & Co sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2020, closing a stake of 11,681 shares — an estimated $151K sold.

D.E. Shaw & Co first reported a position in BLCM in Q2 2017 and held it in 4 quarters. The position peaked at $338K in Q3 2017. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2020.

  • D.E. Shaw & Co reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • D.E. Shaw & Co sold 11,681 Bellicum Pharmaceuticals, Inc. shares in Q1 2020, an estimated $151K.
  • D.E. Shaw & Co first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2017 and held it in 4 quarters.
  • D.E. Shaw & Co's Bellicum Pharmaceuticals, Inc. position peaked at $338K in Q3 2017.
  • 29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2020.

Based on D.E. Shaw & Co's 13F filing for Q1 2020, filed 15 May 2020.